Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSeparating the myths from the clinical picture: facial fat, tirzepatide and the medicines that are actually licensed for weight loss
The biggest misconception: 'Ozempic face' is not caused by Ozempic used for weight loss
'Ozempic face' entered the public conversation as shorthand for the hollow, drawn appearance some people notice around their cheeks, jaw and temples after losing weight on GLP-1 medicines. The name stuck partly because Ozempic was the first semaglutide product to gain wide recognition. The problem is the framing: Ozempic is licensed in the UK for type 2 diabetes management, not for weight loss. If you're using a medicine specifically for weight management, you'd be on Wegovy (semaglutide injection) or Mounjaro (tirzepatide), and if you've ever wondered whether tirzepatide works in a similar way to Ozempic, it carries a different mechanism altogether as the only licensed dual GIP and GLP-1 receptor agonist in the UK.
Facial fat loss is not a side effect that appears on the product labelling for any of these medicines. What it actually reflects is that the face, like the abdomen or thighs, contains adipose tissue. When total body weight falls (by 10%, 15% or more, as seen in trials of both semaglutide and tirzepatide) some of that reduction is visible in the face. The same thing happens with bariatric surgery or any sustained caloric deficit. The medicine accelerates the weight loss; physics does the rest.
If you're worried about what significant weight loss might mean for your appearance, that's a completely understandable concern and one worth raising during your consultation. It won't disqualify you from treatment, but it helps your prescriber understand your goals.
How tirzepatide and semaglutide differ, and why neither 'targets' the face
Neither tirzepatide (Mounjaro) nor semaglutide (Wegovy) directs fat loss to or away from any particular body region. Both medicines reduce appetite and slow gastric emptying, creating conditions in which most people eat less and lose weight over time. Where that weight comes from is governed by individual genetics, body composition and baseline fat distribution, not by which pen you inject.
The clinical distinction between the two medicines is real, though. Tirzepatide activates both the GIP and GLP-1 receptors; semaglutide activates GLP-1 only. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. SURMOUNT-1, the pivotal tirzepatide trial, reported average body-weight reduction of around 20–21% at the 15mg dose. These are population-level averages, and individual results vary considerably.
For a side-by-side look at how Wegovy and Mounjaro compare on efficacy, dosing schedules and eligibility, the Wegovy versus Mounjaro comparison covers the evidence in detail. The short version: both are effective; neither sculpts the face.
What the comparison table actually shows
| Factor | Ozempic (semaglutide) | Wegovy (semaglutide injection) | Mounjaro (tirzepatide) |
|---|---|---|---|
| UK licence for weight loss | No, type 2 diabetes only | Yes | Yes |
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Receptor target | GLP-1 | GLP-1 | Dual GIP + GLP-1 |
| Average weight loss in trials | Not indicated for weight loss | ~15% at 2.4mg (STEP 1, 68 wks) [NEJM] | ~20–21% at 15mg (SURMOUNT-1, 72 wks) [NEJM] |
| Facial fat loss specifically targeted? | No | No | No |
| Available from nume for weight management | No | Yes | Yes |
The table makes one point plainly: 'Ozempic face' is named after a medicine not licensed for weight loss in the UK. The facial changes people notice are a consequence of the weight loss itself, whichever medicine or method brought it about. Ozempic's place in this conversation is more cultural than clinical. For context on how Ozempic and Mounjaro are related (or aren't), the Ozempic and Mounjaro comparison page has the detail, and people sometimes also ask whether Ozempic is actually a tirzepatide, which that page addresses alongside this page clarifying whether tirzepatide and Ozempic are the same thing.
What IS licensed for weight loss in the UK, and how to access it
The two medicines with a UK licence for weight management in adults are Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk). Both are prescription-only medicines, you cannot obtain them legally without a prescription following a clinical assessment. NICE has appraised both: tirzepatide under TA1026 and semaglutide under TA875, each with specific eligibility criteria. Private treatment through a regulated pharmacy bypasses NHS waiting lists for people who meet the licensed criteria, which differ from NICE's NHS thresholds.
At nume, a GPhC-registered Independent Prescriber reads your consultation the same day, a clinician, not a queue of software checks. Both Wegovy and Mounjaro are available through our treatment pathway for adults who are clinically suitable, typically those with a BMI of 30 or above, or 27 or above with a relevant weight-related condition. If you want to understand how the two medicines compare on cost as well as efficacy, the Mounjaro and Wegovy price comparison is a practical starting point.
Which medicine suits you is a clinical decision reached with our prescribers, not one this page can make. Facial changes during significant weight loss are worth discussing, but they're one factor in a larger picture. Speak to our prescribers to explore which option fits your health history and goals.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.